Bictegravir/lenacapavir (Bixlenvo) vs Raltegravir

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV integrase · full HIV pipeline

Bictegravir/lenacapavir (Bixlenvo)

Marketed by Gilead Sciences

Approved in HIVsmall molecule
Partial signal

NCT05502341 · Phase 2/3 · active, not recruiting

This was a randomized, active-controlled trial in 557 people in its Phase 3 part, but it was open-label, so participants and investigators knew which treatment each person received. Its primary endpoint, the proportion with detectable HIV-1 RNA at week 48, is an objective laboratory measure, and bictegravir/lenacapavir met the non-inferiority goal against continued complex regimens.

Next expected readout: July 2028 · NCT07908446 (registry estimate)

Reported efficacy

Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm; Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm: Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results). (met)

Result source: NCT05502341

Raltegravir · Isentress

Marketed by Merck & Co.

Approved in HIVsmall molecule
Reliable signal

NCT00293254 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial with 351 patients, using HIV-1 RNA suppression - a regulator-accepted, disease-defining measure - as the primary endpoint. The raltegravir arm showed clearly higher suppression rates than placebo at both Week 16 and Week 48, with confidence intervals that do not overlap, indicating a statistically robust and clinically meaningful benefit.

Next expected readout: January 2028 · NCT02140255 (registry estimate)

Reported efficacy

Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks); Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 48 (48 Weeks); Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA <400 Copies/mL (156 Weeks); Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA <400 Copies/mL (240 Weeks): Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks): Raltegravir 400 mg b.i.d. + OBT 77.3% (95% CI 71.3 to 82.6) vs Placebo + OBT 42.9% (95% CI 33.8 to 52.3) (met)

Result source: NCT00293254

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBictegravir/​lenacapavir (Bixlenvo)Raltegravir
HIV-1 RNA below 50 copies/mL (week 48)—Trial running · NCT06532656—Not posted · NCT01195467
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT06532656—Not posted · NCT01195467
CD4 count, change (week 48)—Trial running · NCT06532656157.2 vs 54.2+103 vs placebo400 mg b.i.d. · wk 156 · n 189NCT00293254
6 other results
  • 170.9 vs 71.0 400 mg b.i.d · wk 156 · n 207 · Phase 3 · secondary NCT00293267
  • 98.4 vs 39.8 400 mg b.i.d. · wk 48 · n 217 · Phase 3 · secondary NCT00293254
  • 120.2 vs 49.4 400 mg b.i.d · wk 48 · n 230 · Phase 3 · secondary NCT00293267
  • 8.6 vs 21.9 wk 24 · n 19 · Phase 4 · primary NCT00772590
  • 2.7 vs 21.9 wk 24 · n 19 · Phase 4 · primary NCT00772590
  • 192 vs 205 wk 48 · n 9 · Phase 4 · primary NCT00762892

HIV-1 RNA below 50 copies/mL (week 48)

Bictegravir/​lenacapavir (Bixlenvo)
—Trial running · NCT06532656
Raltegravir
—Not posted · NCT01195467

HIV-1 RNA 50 copies/mL or more (week 48)

Bictegravir/​lenacapavir (Bixlenvo)
—Trial running · NCT06532656
Raltegravir
—Not posted · NCT01195467

CD4 count, change (week 48)

Bictegravir/​lenacapavir (Bixlenvo)
—Trial running · NCT06532656
Raltegravir
157.2 vs 54.2+103 vs placebo400 mg b.i.d. · wk 156 · n 189NCT00293254
6 other results
  • 170.9 vs 71.0 400 mg b.i.d · wk 156 · n 207 · Phase 3 · secondary NCT00293267
  • 98.4 vs 39.8 400 mg b.i.d. · wk 48 · n 217 · Phase 3 · secondary NCT00293254
  • 120.2 vs 49.4 400 mg b.i.d · wk 48 · n 230 · Phase 3 · secondary NCT00293267
  • 8.6 vs 21.9 wk 24 · n 19 · Phase 4 · primary NCT00772590
  • 2.7 vs 21.9 wk 24 · n 19 · Phase 4 · primary NCT00772590
  • 192 vs 205 wk 48 · n 9 · Phase 4 · primary NCT00762892
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Bictegravir/lenacapavir (Bixlenvo)
Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results). NCT05502341 · Phase 2/3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Bictegravir/lenacapavir (Bixlenvo): 0 of 4 rows · Raltegravir: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRaltegravir
Dropout rate
23.7%400 mg b.i.d.a
NCT00293254 · Phase 3 · combination
show 27 more results
—400 mg b.i.d.
NCT00293254 · Phase 3 · combination
—400 mg b.i.d
NCT00293267 · Phase 3 · combination
17.5%400 mg b.i.d
NCT00293267 · Phase 3 · combination
25.5%400 mg b.i.d.
NCT00369941 · Phase 3
15.4%
NCT01147107 · Phase 4 · registry result, not featured evidence
9.5%
NCT03374358 · Phase 4 · registry result, not featured evidence
0%
NCT03667547 · Phase 4 · registry result, not featured evidence
—Arm A Raltegravir
NCT03205566 · Phase 4 · registry result, not featured evidence
—Arm B Raltegravir Lamivudine
NCT03205566 · Phase 4 · registry result, not featured evidence · combination
10.5%
NCT02383355 · Phase 4 · registry result, not featured evidence
38.5%
NCT00939874 · Phase 4 · registry result, not featured evidence
0%
NCT00843713 · Phase 4 · registry result, not featured evidence
22.2%
NCT01332227 · Phase 4 · registry result, not featured evidence · combination
27.3%
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
6.7%Switch to Tenofovir/Emtricitabine
NCT01270802 · Phase 4 · registry result, not featured evidence · combination
—Switch to Tenofovir/Emtricitabine/
NCT01270802 · Phase 4 · registry result, not featured evidence
35.7%
NCT00762892 · Phase 4 · registry result, not featured evidence
0%
NCT01335620 · Phase 4 · registry result, not featured evidence · combination
6.7%Intervention Arm No.1
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
28.6%Intervention Arm No.2
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
0%Hyper-immune Bovine Colostrum
NCT00772590 · Phase 4 · registry result, not featured evidence
0%Raltegravir + Hyper-immune Bovine
NCT00772590 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00631449 · Phase 4 · registry result, not featured evidence
7.5%1200 mg QD
NCT03029689 · Phase 3 · registry result, not featured evidence · combination
4.1%
NCT02284035 · Phase 3 · registry result, not featured evidence · combination
—1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
12.4%Reformulated Raltegravir
NCT02131233 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
0.9%400 mg b.i.d.a
NCT00293254 · Phase 3 · combination
show 27 more results
—400 mg b.i.d.
NCT00293254 · Phase 3 · combination
—400 mg b.i.d
NCT00293267 · Phase 3 · combination
0.4%400 mg b.i.d
NCT00293267 · Phase 3 · combination
5%400 mg b.i.d.
NCT00369941 · Phase 3
—
NCT01147107 · Phase 4 · registry result, not featured evidence
—
NCT03374358 · Phase 4 · registry result, not featured evidence
—
NCT03667547 · Phase 4 · registry result, not featured evidence
—Arm A Raltegravir
NCT03205566 · Phase 4 · registry result, not featured evidence
—Arm B Raltegravir Lamivudine
NCT03205566 · Phase 4 · registry result, not featured evidence · combination
10.5%
NCT02383355 · Phase 4 · registry result, not featured evidence
—
NCT00939874 · Phase 4 · registry result, not featured evidence
—
NCT00843713 · Phase 4 · registry result, not featured evidence
5.6%
NCT01332227 · Phase 4 · registry result, not featured evidence · combination
—
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
0%Switch to Tenofovir/Emtricitabine
NCT01270802 · Phase 4 · registry result, not featured evidence · combination
—Switch to Tenofovir/Emtricitabine/
NCT01270802 · Phase 4 · registry result, not featured evidence
—
NCT00762892 · Phase 4 · registry result, not featured evidence
—
NCT01335620 · Phase 4 · registry result, not featured evidence · combination
0%Intervention Arm No.1
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
7.1%Intervention Arm No.2
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
—Hyper-immune Bovine Colostrum
NCT00772590 · Phase 4 · registry result, not featured evidence
—Raltegravir + Hyper-immune Bovine
NCT00772590 · Phase 4 · registry result, not featured evidence · combination
—
NCT00631449 · Phase 4 · registry result, not featured evidence
—1200 mg QD
NCT03029689 · Phase 3 · registry result, not featured evidence · combination
—
NCT02284035 · Phase 3 · registry result, not featured evidence · combination
—1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
1.3%Reformulated Raltegravir
NCT02131233 · Phase 3 · registry result, not featured evidence
Serious AEs
—400 mg b.i.d.a
NCT00293254 · Phase 3 · combination
show 27 more results
34.8%400 mg b.i.d.
NCT00293254 · Phase 3 · combination
41.8%400 mg b.i.d
NCT00293267 · Phase 3 · combination
—400 mg b.i.d
NCT00293267 · Phase 3 · combination
20.3%400 mg b.i.d.
NCT00369941 · Phase 3
21.1%
NCT01147107 · Phase 4 · registry result, not featured evidence
0%
NCT03374358 · Phase 4 · registry result, not featured evidence
0%
NCT03667547 · Phase 4 · registry result, not featured evidence
0%Arm A Raltegravir
NCT03205566 · Phase 4 · registry result, not featured evidence
0%Arm B Raltegravir Lamivudine
NCT03205566 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02383355 · Phase 4 · registry result, not featured evidence
13.5%
NCT00939874 · Phase 4 · registry result, not featured evidence
3.8%
NCT00843713 · Phase 4 · registry result, not featured evidence
5.6%
NCT01332227 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
—Switch to Tenofovir/Emtricitabine
NCT01270802 · Phase 4 · registry result, not featured evidence · combination
0%Switch to Tenofovir/Emtricitabine/
NCT01270802 · Phase 4 · registry result, not featured evidence
7.1%
NCT00762892 · Phase 4 · registry result, not featured evidence
0%
NCT01335620 · Phase 4 · registry result, not featured evidence · combination
13.3%Intervention Arm No.1
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
14.3%Intervention Arm No.2
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
0%Hyper-immune Bovine Colostrum
NCT00772590 · Phase 4 · registry result, not featured evidence
5.3%Raltegravir + Hyper-immune Bovine
NCT00772590 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00631449 · Phase 4 · registry result, not featured evidence
0%1200 mg QD
NCT03029689 · Phase 3 · registry result, not featured evidence · combination
6.1%
NCT02284035 · Phase 3 · registry result, not featured evidence · combination
9.6%1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
—Reformulated Raltegravir
NCT02131233 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
400 mg b.i.d.a
upper respiratory tract infection 33% (placebo 24.4%)
diarrhoea 32.6% (placebo 29.4%)
fatigue 19.6% (placebo 15.1%)
NCT00293254 · Phase 3 · combination
show 17 more results
400 mg b.i.d
diarrhoea 31.9% (placebo 28.8%)
nasopharyngitis 25% (placebo 17.8%)
bronchitis 18.1% (placebo 13.6%)
NCT00293267 · Phase 3 · combination
400 mg b.i.d.
nasopharyngitis 26.7%
headache 26%
diarrhoea 25.6%
NCT00369941 · Phase 3
alt elevation 55.3%
NCT01147107 · Phase 4 · registry result, not featured evidence
sleeping difficulties 52.6% (placebo 54.2%)
gastrointestinal (diarrhoea, nausea) 47.4% (placebo 29.2%)
headache 47.4% (placebo 33.3%)
NCT03374358 · Phase 4 · registry result, not featured evidence
runny nose 10.5%
cold 5.3%
diarrhoea 5.3%
NCT03205566 · Phase 4 · registry result, not featured evidence
nightmares and vivid dreams 13.2%
diarrhoea 7.9%
headache 7.9%
NCT03205566 · Phase 4 · registry result, not featured evidence · combination
headache 5.3%
insomnia 5.3%
NCT02383355 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 18.9%
diarrhoea 10.8%
abdominal cramps 5.4%
NCT00939874 · Phase 4 · registry result, not featured evidence
hyperbilirubinemia 3.8% (placebo 0%)
NCT00843713 · Phase 4 · registry result, not featured evidence
hyperbilirubinaemia 8.3%
ocular icterus 8.3%
bronchitis 5.6%
NCT01332227 · Phase 4 · registry result, not featured evidence · combination
gastrointestinal intolerance 9.1%
neuropsychiatric side effect 0%
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
neutropenia 6.7%
diastolic hypertension 0%
impaired fasting glucose 0%
NCT01270802 · Phase 4 · registry result, not featured evidence
bronchitis 20%
diarrhea 20%
headache 20%
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
diarrhea 21.4%
upper respiratory infection 21.4%
fatigue 14.3%
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
1200 mg QD
adverse event not related to the treatment 2.6% (placebo 5.6%)
NCT03029689 · Phase 3 · registry result, not featured evidence · combination
insomnia 8.2%
amigdalitis 6.1%
common cold 6.1%
NCT02284035 · Phase 3 · registry result, not featured evidence · combination
1200 mg QD + Truvada
headache 15.8%
nausea 13.6%
diarrhoea 13.4%
NCT02131233 · Phase 3 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Raltegravir

HIV RNA Less Than 400 Copies 77.3% (n=229) vs 42.9% (n=119) placebo @ 16wk400 mg b.i.d.
responder rate · % of participants
NCT00293254 · Phase 3 · combination
show 5 more results
71.1% (n=228) vs 37.8% (n=119) placebo @ 48wk400 mg b.i.d.
NCT00293254 · Phase 3 · combination
50.2% (n=229) vs 21% (n=119) placebo @ 156wk400 mg b.i.d.
NCT00293254 · Phase 3 · combination
77.7% (n=229) vs 41% (n=117) placebo @ 16wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
73.6% (n=231) vs 36.4% (n=118) placebo @ 48wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
57.3% (n=232) vs 25.6% (n=117) placebo @ 156wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
HIV RNA Less Than 400 Copies 45.7% (n=230) vs 13.4% (n=119) placebo @ 240wk400 mg b.i.d.
responder rate · % of participants
Extension (open-label)
NCT00293254 · Phase 3 · combination
show 1 more result
45.3% (n=232) vs 20.3% (n=118) placebo @ 240wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
HIV RNA Less Than 50 Copies 62% (n=229) vs 36.1% (n=119) placebo @ 16wk400 mg b.i.d.
responder rate · % of participants
NCT00293254 · Phase 3 · combination
show 5 more results
59.6% (n=228) vs 34.5% (n=119) placebo @ 48wk400 mg b.i.d.
NCT00293254 · Phase 3 · combination
47.6% (n=229) vs 17.6% (n=119) placebo @ 156wk400 mg b.i.d.
NCT00293254 · Phase 3 · combination
61.6% (n=229) vs 33.3% (n=117) placebo @ 16wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
64.5% (n=231) vs 31.4% (n=118) placebo @ 48wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
53.4% (n=232) vs 25.6% (n=117) placebo @ 156wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
HIV RNA Less Than 50 Copies 41.3% (n=230) vs 13.4% (n=119) placebo @ 240wk400 mg b.i.d.
responder rate · % of participants
Extension (open-label)
NCT00293254 · Phase 3 · combination
show 1 more result
42.2% (n=232) vs 18.6% (n=118) placebo @ 240wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
Without Loss of Virologic 44.3% (n=230) vs 17.6% (n=119) placebo @ 156wk400 mg b.i.d.
responder rate · % of participants
NCT00293254 · Phase 3 · combination
HIV-1 RNA -1.92 vs -1.06 placebo copies/mL @ 16wk400 mg b.i.d.
absolute change · copies/mL
NCT00293254 · Phase 3 · combination
show 6 more results
-1.75 vs -0.87 placebo copies/mL @ 48wk400 mg b.i.d.
NCT00293254 · Phase 3 · combination
-1.37 vs -0.52 placebo copies/mL @ 156wk400 mg b.i.d.
NCT00293254 · Phase 3 · combination
-1.85 vs -0.78 placebo copies/mL @ 16wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
-1.67 vs -0.68 placebo copies/mL @ 48wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
-1.44 vs -0.51 placebo copies/mL @ 156wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
-3.05 vs -3.29 Atazanavir copies/mL @ 48wk
NCT00762892 · Phase 4 · registry result, not featured evidence
HIV-1 RNA -1.31 vs -0.41 placebo copies/mL @ 240wk400 mg b.i.d.
absolute change · copies/mL
Extension (open-label)
NCT00293254 · Phase 3 · combination
show 1 more result
-1.24 vs -0.45 placebo copies/mL @ 240wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
CD4+ 85.8 vs 39.9 placebo cells/uL @ 16wk400 mg b.i.d.
absolute change · cells/uL
NCT00293254 · Phase 3 · combination
show 8 more results
98.4 vs 39.8 placebo cells/uL @ 48wk400 mg b.i.d.
NCT00293254 · Phase 3 · combination
157.2 vs 54.2 placebo cells/uL @ 156wk400 mg b.i.d.
NCT00293254 · Phase 3 · combination
82.7 vs 31.3 placebo cells/uL @ 16wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
120.2 vs 49.4 placebo cells/uL @ 48wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
170.9 vs 71.03 placebo cells/uL @ 156wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
192 vs 205 Atazanavir cells/uL @ 48wk
NCT00762892 · Phase 4 · registry result, not featured evidence
8.62 vs 21.87 placebo cells/uL @ 24wk
NCT00772590 · Phase 4 · registry result, not featured evidence · combination
2.68 vs 21.87 placebo cells/uL @ 24wk
NCT00772590 · Phase 4 · registry result, not featured evidence
CD4+ 172.1 vs 54.1 placebo cells/uL @ 240wk400 mg b.i.d.
absolute change · cells/uL
Extension (open-label)
NCT00293254 · Phase 3 · combination
show 1 more result
193.6 vs 68.2 placebo cells/uL @ 240wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
HIV-1 RNA Less Than 400 Copies Per 86.1% (n=280) vs 81.9% (n=281) Efavirenz @ 48wk400 mg b.i.d.
event count · % of participants
NCT00369941 · Phase 3 · converted to % from 241 Participants as posted
show 7 more results
90% (n=280) vs 85.8% (n=281) Efavirenz @ 48wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 252 Participants as posted
81.1% (n=281) vs 78.7% (n=282) Efavirenz @ 96wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 228 Participants as posted
85.4% (n=281) vs 81.2% (n=282) Efavirenz @ 96wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 240 Participants as posted
75.4% (n=281) vs 68.1% (n=282) Efavirenz @ 156wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 212 Participants as posted
79.7% (n=281) vs 72% (n=282) Efavirenz @ 156wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 224 Participants as posted
71% (n=279) vs 61.3% (n=279) Efavirenz @ 240wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 198 Participants as posted
73.8% (n=279) vs 64.9% (n=279) Efavirenz @ 240wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 206 Participants as posted
CD4 189.1 vs 163.3 Efavirenz count @ 48wk400 mg b.i.d.
absolute change · count
NCT00369941 · Phase 3
show 3 more results
239.6 vs 224.8 Efavirenz count @ 96wk400 mg b.i.d.
NCT00369941 · Phase 3
331.7 vs 295.2 Efavirenz count @ 156wk400 mg b.i.d.
NCT00369941 · Phase 3
373.7 vs 311.6 Efavirenz count @ 240wk400 mg b.i.d.
NCT00369941 · Phase 3
Hepatic Fat Fraction 0.6 vs 0.3 placebo fraction @ 24wk
absolute change · fraction
NCT03374358 · Phase 4 · registry result, not featured evidence

+ 22 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bictegravir/lenacapavir (Bixlenvo)'s landscape · Raltegravir's landscape